Fosfomycin susceptibility of uropathogens at Charlotte Maxeke Johannesburg Academic Hospital

Southern African Journal of Infectious Diseases

 
 
Field Value
 
Title Fosfomycin susceptibility of uropathogens at Charlotte Maxeke Johannesburg Academic Hospital
 
Creator Mothibi, Lesego M. Bosman, Norma N. Nana, Trusha
 
Subject Clinical Microbiology; Infectious diseases. fosfomycin susceptibility; urinary tract infections; uropathogens; multidrug-resistant organisms; ciprofloxacin resistance; hospital; ambulatory.
Description Background: Multidrug-resistant uropathogens are becoming widespread both in community and hospital setting. Safe yet effective treatments are a priority. Fosfomycin is an antibacterial that displays good activity against most bacteria causing urinary tract infections (UTIs), including multidrug-resistant bacteria. The aim of this study was to evaluate fosfomycin susceptibility for uropathogens isolated from a microbiology laboratory at a tertiary academic hospital. In addition, this was compared to the susceptibility of other oral antimicrobials.Methods: We conducted a retrospective analysis of laboratory reports for uropathogens isolated at Charlotte Maxeke Johannesburg Academic Hospital from September 2015 to August 2017. Antimicrobial susceptibility testing of the isolates was performed using the Kirby–Bauer disk diffusion method or the Vitek® 2 system according to the Clinical and Laboratory Standards Institute.Results: Overall susceptibility of fosfomycin for the 4700 Enterobacteriaceae isolates was 95.7%; 95% confidence interval (CI) 95.1–96.2. The overall susceptibility for fosfomycin against the gram-positives was 98.6%. There were 37.9% multidrug-resistant Enterobacteriaceae (MDRE) isolated during the study period. Fosfomycin displayed activity against 94.4% of extended-spectrum β-lactamase (ESBL) producers and 90.7% for carbapenem-resistant Enterobacteriaceae (CRE). None of the methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus isolates tested was fosfomycin resistant. The overall in vitro susceptibility was significantly higher for fosfomycin (p = 0.0001) compared to amoxicillin/clavulanic acid, cephalexin, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole and nitrofurantoin.Conclusion: This study confirmed the high susceptibility of fosfomycin against UTI pathogens isolated at our institution. In an era of increasing antimicrobial resistance, fosfomycin represents a potential option for the treatment of UTIs at Charlotte Maxeke Johannesburg Academic Hospital.
 
Publisher AOSIS Publishing
 
Contributor Department of Clinical Microbiology & Infectious Diseases University of the Witwatersrand
Date 2020-10-26
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Retrospective; Laboratory-based study
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajid.v35i1.173
 
Source Southern African Journal of Infectious Diseases; Vol 35, No 1 (2020); 8 pages 2313-1810 2312-0053
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajid.co.za/index.php/sajid/article/view/173/392 https://sajid.co.za/index.php/sajid/article/view/173/391 https://sajid.co.za/index.php/sajid/article/view/173/393 https://sajid.co.za/index.php/sajid/article/view/173/390
 
Coverage Johannesburg; South Africa September 2015 to August 2017 Age
Rights Copyright (c) 2020 Lesego M. Mothibi, Norma N. Bosman, Trusha Nana https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT